Skip to content

Advertisement

  • Oral presentation
  • Open Access

Can Vaccine-induced Mucosal High Avidity CD8+ CTL Delay AIDS-viral Dissemination from Mucosa?

  • 1,
  • 2,
  • 3,
  • 4,
  • 1,
  • 1,
  • 5,
  • 5,
  • 6,
  • 7,
  • 3,
  • 1 and
  • 1Email author
Retrovirology20052 (Suppl 1) :S100

https://doi.org/10.1186/1742-4690-2-S1-S100

  • Published:

Keywords

  • Infectious Disease
  • Cancer Research
  • Systemic Circulation
  • Systemic Dissemination
  • Viral Transmission

Natural HIV transmission occurs through mucosa, but it is debated whether mucosal cytotoxic T lymphocytes (CTL) can prevent or reduce dissemination from the initial mucosal site to the systemic circulation. Also, the role of CTL avidity in mucosal AIDS viral transmission is unknown. To address these questions, we used delay in acute-phase peak viremia after intrarectal challenge as an indicator of systemic dissemination. We find that a peptide-prime/poxviral boost vaccine inducing high levels of high avidity mucosal CTL can impact dissemination of intrarectally administered pathogenic SHIV-ku2 in macaques, and that such protection correlates better with mucosal than with systemic CTL and particularly with levels of high avidity mucosal CTL.

Notes

Authors’ Affiliations

(1)
Vaccine Branch, NCI, NIAID, NIH, Bethesda, MD 20892, USA
(2)
Division of Information and Mathematical Sciences, Genome Institute of Singapore, 138672, Singapore
(3)
Laboratory Of Clinical Investigation, NIAID, NIH, Bethesda, MD 20892, USA
(4)
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
(5)
Advanced BioScience Laboratories, Inc., Kensington, MD 20895, USA
(6)
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA
(7)
Southern Research Institute, Frederick, MD, USA

Copyright

Advertisement